- US-listed companies
- Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc.AVTE
Market cap
$56.72M
P/E ratio
Dec 31, 2021 | Dec 31, 2022 | |
Research and development | 15 | 39 |
General and administrative | 8 | 15 |
Total operating expenses | 23 | 53 |
Loss from operations | -23 | -53 |
Interest income | 0 | 2 |
Other expense | 0 | 0 |
Total other income | 0 | 2 |
Net loss before income taxes | -23 | -51 |
Total tax provision | 0 | 0 |
Net loss | -23 | -52 |
Net loss | -23 | -52 |
Unrealized loss on securities | 0 | 0 |
Comprehensive loss | -23 | -52 |
Net loss per share, basic | - | -2.1 |
Net loss per share, diluted | - | -2.1 |